Transesophageal color Doppler diagnosis of anomalous origin of left circumflex coronary artery.

T. Samdarshi,D. Hill,N. Nanda

DOI: https://doi.org/10.1016/0002-8703(91)91018-I

IF: 5.099

1991-08-01

American Heart Journal

Abstract:

What problem does this paper attempt to address?

Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer

B. Gori,S. Ricciardi,E. del Signore,A. Fulvi,F. de Marinis

DOI: https://doi.org/10.1517/14728222.2011.652617

IF: 6.797

2012-03-24

Expert Opinion on Therapeutic Targets

Abstract:Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of ‘molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.
Quantification of low-level Cytomegalovirus and Epstein-Barr virus DNAemia by digital PCR

DeVon N. Hunter-Schlichting,Rachel I. Vogel,Melissa A Geller,Heather H. Nelson

DOI: https://doi.org/10.1016/j.jviromet.2023.114876

IF: 2.623

2024-01-06

Journal of Virological Methods

Abstract:Background Digital PCR (dPCR) can quantify cell-free viral DNA (DNAemia), a biomarker of active viral infection. To accelerate epidemiologic investigation into low-level viral reactivation in chronic disease, we have evaluated the performance of dPCR to detect cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNAemia across platforms and blood matrices. Methods The droplet-based (BioRad) dPCR platform performance was compared to chip-based (BioMark), and assay validation followed dMIQE guidelines. CMV and EBV DNA reference materials were spiked into known negative plasma and serum samples. In addition, two independent cohorts of ovarian cancer patients were evaluated for viral DNAemia (n=65 serum and 79 plasma samples). Results The limit of quantification (LOQ) was at or slightly above 100 copies/mL for both instruments: 105-135 copies/mL for droplet-based detection and 100 copies/mL for chip-based detection. DNAemia in serum had a slightly lower LOQ (105-110 copies/mL) compared to plasma (LOQ; 115-135 copies/mL). The variation (CV) coefficients for each assay and machine were less than 5%. In patient samples, CVs ranged from 4.5 – 7.4% and were similar for cell-free DNA derived from serum or plasma. There was good correlation between DNAemia measurements in patient samples across dPCR platforms (r>0.90 for each assay and matrix). Conclusion dPCR can quantify low-level herpes virus DNAemia with CVs below 8%. Our results indicate that using serum-derived cell-free DNA and droplet-based dPCR is optimal for quantitating low-level viral DNAemia; however, plasma and chip-based approaches are acceptable alternatives and suitable for epidemiologic investigation.

biochemical research methods,biotechnology & applied microbiology,virology
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas

Kwok Hung Yu,Y M Dennis Lo,Gary M Tse,K C Allen Chan,Amy B W Chan,Katherine C K Chow,Tony K F Ma,Alexander C Vlantis,Sing Fai Leung,C Andrew van Hasselt,Philip J Johnson,Anthony T C Chan

DOI: https://doi.org/10.1158/1078-0432.ccr-0991-3

2004-03-01

Abstract:Purpose: We investigated the detectability of EBV DNA in the plasma of patients with non-nasopharyngeal head and neck carcinomas (NNHNC). Previous studies have shown that EBV is present in the tumor tissue of some NNHNC. Experimental design: We recruited 101 patients with NNHNC and 48 healthy controls. Blood samples were taken from controls and patients before treatment. Tumor tissue samples were tested for the presence of EBV in the first 69 patients by in situ hybridization for small EBV-encoded RNA (EBER). Plasma EBV DNA was measured by real-time quantitative PCR in patients and controls. Results: Squamous cell carcinoma (SCC) was the commonest histology (78 patients) followed by lymphoepithelial carcinoma (8 patients). EBER was detected in tumor cells in 7 of 69 patients tested. All of the EBER-positive tumors were lymphoepithelial carcinoma. Two controls (2 of 48; 4.2%) had detectable plasma EBV DNA. Plasma EBV DNA was detected in all of the patients with EBER-positive tumors, and in 23 of 94 (24.5%) patients with tumors of EBER-negative or unknown status. The proportion of plasma EBV DNA-positive cases in either group was significantly higher than that in the control group (P < 0.0027). Plasma EBV DNA concentrations in patients with EBER-positive tumors (median, 3827 copies/ml) were significantly higher than those in the controls (median, 0 copy/ml; P = 0.0001). Of patients with SCC, 21 (26.9%) had detectable plasma EBV DNA (median concentration, 34 copies/ml). Plasma EBV DNA concentrations in the whole group of patients with SCC (median, 0 copy/ml; interquartile range, 0-4 copies/ml) were also significantly higher than those in the controls (P = 0.001). Conclusions: Our data indicate that plasma EBV DNA reflects tumoral EBER status, and it may be of use as a tumor marker for EBER-positive NNHNC. The biological and clinical significance of low levels of circulating EBV DNA in the minority of patients with EBER-negative tumors remain to be elucidated.
Evaluation of Performance and Application of Three Nucleic Acid Extraction Methods for Quantification of Plasma Epstein-Barr Virus DNA

Zheng Yuhong,Chen Yansong,Pan Jianji,Lin Shaojun,Xiao Zhenzhou,Zong Jingfeng,Lin Yingying,Guo Qiaojuan,Xu Yuanji,Chen Yan

DOI: https://doi.org/10.3760/cma.j.issn.1009-9158.2018.01.013

2018-01-01

Abstract:Objective To evaluate and compare the analytical performances and application values of three nucleic acid extraction methods for quantification of plasma Epstein-Barr Virus ( EBV ) DNA. Methods It used silica membrane spin column , boiling and automated magnetic bead method to extract viral nucleic acid in parallel , and combined real-time fluorescence quantitative PCR assays for quantitative EBV-DNA quantification.The performances of three methods were determined and compared by using the third-party reference materials , and the clinical values were analyzed by pairing detecting 100 NPC patients and 100 healthy subjects in pair .Results The accuracy and imprecision of three methods were all in line with requirements , and the results of clinical samples were linearly correlated . But actually the reproducibility and intermediate imprecision of the magnetic bead method were smaller and stable than those of the spin column method and the boiling method ( all <3％);the limit of detection for the magnetic bead method was 3.334 ×101 IU/ml, better than that of spin column method (4.159 ×101 IU/ml) and boiling method (8.511 ×101 IU/ml);the linear range of the magnetic bead method was 5.4 ×101 -5.4 ×105 IU/ml, slightly wider than that of the boiling method (5.4 ×102 -5.4 ×105 IU/ml); the ability of anti -Hb interference ability of magnetic bead method is better than that of boiling method ;and the positive rate and the mean viral load of the NPC samples measured with the magnetic bead method were significantly higher (95％, 8.342 ×103 IU/ml) than those measured with the spin column method (84％, 4.707 ×103 IU/ml) and the boiling method (78％, 2.571 ×103 IU/ml) ( P all<0.05).Conclusion The automated magnetic bead nucleic acid extraction method offered better analytical performance and higher clinical value for EBV DNA quantification in plasma .
Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

Zhiling Yan,Qian Sun,Huanxin Zhang,Yahui Han,Jianlin Qiao,Mingshan Niu,Shengyun Zhu,Kai Zhao,Qingyun Wu,Hai Cheng,Jiang Cao,Lingyu Zeng,Zhenyu Li,Kailin Xu

DOI: https://doi.org/10.3892/ol.2019.10861

2019-01-01

Oncology Letters

Abstract:Quantitative monitoring of BCR-ABL1 IS gene using reverse transcription quantitative-PCR (RT-qPCR) is an important method for evaluating the treatment effects in patients with chronic myeloid leukemia (CML). Digital-PCR (dPCR) can be applied to detect the BCR-ABL1 gene with high sensitivity. In the present study, the results of the Clarity™ dPCR system were compared with those of the RT-qPCR in order to determine whether dPCR can be applied in the clinical setting. A total of 83 patients were included in the present study, and they were divided into two groups according to the results of BCR-ABL1 IS during ongoing monitoring. A total of 43 patients with undetectable BCR-ABL1 IS where enrolled in group A. BCR-ABL1 testing was performed using the dPCR system on the same peripheral blood samples of patients from group A, and the association between dPCR results and relapse was analyzed. The RT-qPCR platform and dPCR system were used simultaneously to detect the BCR-ABL1 gene of another 40 patients who achieved either partial cytogenetic response (PCyR) or further response. Among patients with undetectable BCR-ABL1 IS, patients with dPCR-positive disease (BCR-ABL1 >0.1%) were more likely to undergo molecular relapse (P=0.018). The results of dPCR detection of BCR-ABL1% were consistent with the RT-qPCR results (R2=0.9510) in patients who achieved PCyR or further response. For samples with BCR-ABL1 IS <1.0%, the consistency of the dPCR and RT-qPCR results was better than that of BCR-ABL1 IS >1.0% (R2=0.9488 vs. R2=0.9264 for BCR-ABL1 IS). The detection results of the BCR-ABL1 gene in patients with CML using dPCR matched well with those from the RT-qPCR. To conclude, the results of the dPCR system can be applied as a supplement to the RT-qPCR platform, particularly for those with BCR-ABL1 IS <1.0%.
Performance and Operational Feasibility of Epstein-Barr Virus–Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches

Pei-Jen Lou,W.K. Jacky Lam,Wan-Lun Hsu,Ruth M. Pfeiffer,Kelly J. Yu,Charles M.L. Chan,Vicky C.T. Lee,Tseng-Cheng Chen,Shyuang-Der Terng,Yung-An Tsou,Yi-Shing Leu,Li-Jen Liao,Yen-Liang Chang,Yin-Chu Chien,Cheng-Ping Wang,Ching-Yuan Lin,Chun-Hung Hua,Jehn-Chuan Lee,Tsung-Lin Yang,Chu-Hsing Hsiao,Ming-Shiang Wu,Ming-Hsui Tsai,Hung-Chun Cheng,Allan Hildesheim,Chien-Jen Chen,K.C. Allen Chan,Zhiwei Liu,Wan-Lun Hsu,Yin-Chu Chien,Chien-Jen Chen,Allan Hildesheim,Ruth M. Pfeiffer,Zhiwei Liu,Kelly J. Yu,Cheng-Ping Wang,Tsung-Lin Yang,Pei-Jen Lou,Chun-Nan Chen,Tseng-Cheng Chen,Chih-Feng Lin,James Jer-Min Jian,Skye Hongiun Cheng,Yu-Chen Tsai,Yih-Lin Chung,Jia-Shing Wu,Ming-Jiung Liu,Kuei-Kang Huang,Mei-Hua Tsou,Hsin-Hsuan Chen,Ching-Yuan Lin,Shyuang-Der Terng,Fang-Yin Lin,Hsin-I Huang,Hung-Chun Cheng,Yung-An Tsou,Chun-Hung Hua,Ming-Hsui Tsai,Yi-Shing Leu,Jehn-Chuan Lee,Li-Jen Liao,Yen-Liang Chang,Chu-Hsing Hsiao,Ming-Shiang Wu,GEV-NPC Group on behalf of the Collaborative Group

DOI: https://doi.org/10.1200/jco.22.01979

IF: 45.3

2023-07-23

Journal of Clinical Oncology

Abstract:PURPOSE Two Epstein-Barr virus (EBV)–based testing approaches have shown promise for early detection of nasopharyngeal carcinoma (NPC). Neither has been independently validated nor their performance compared. We compared their diagnostic performance in an independent population. METHODS We tested blood samples from 819 incident Taiwanese NPC cases (213 early-stage, American Joint Committee on Cancer version 7 stages I and II) diagnosed from 2010 to 2014 and from 1,768 controls from the same region, frequency matched to cases on age and sex. We compared an EBV antibody score using immunoglobulin A antibodies measured by enzyme-linked immunosorbent assay (EBV antibody score) and plasma EBV DNA load measured by real-time PCR followed by next-generation sequencing (NGS) among EBV DNA–positive individuals (EBV DNA algorithm). RESULTS EBV antibodies and DNA load were measured for 2,522 (802 cases; 1,720 controls) and 2,542 (797 cases; 1,745 controls) individuals, respectively. Of the 898 individuals positive for plasma EBV DNA and therefore eligible for NGS, we selected 442 (49%) for NGS testing. The EBV antibody score had a sensitivity of 88.4% (95% CI, 86.1 to 90.6) and a specificity of 94.9% (95% CI, 93.8 to 96.0) for NPC. The EBV DNA algorithm yielded significantly higher sensitivity (93.2%; 95% CI, 91.3 to 94.9; P = 1.33 × 10 −4 ) and specificity (98.1%; 95% CI, 97.3 to 98.8; P = 3.53 × 10 −7 ). For early-stage NPC, the sensitivities were 87.1% (95% CI, 82.7 to 92.4) for the EBV antibody score and 87.0% (95% CI, 81.9 to 91.5) for the EBV DNA algorithm ( P = .514). For regions with a NPC incidence of 20-100/100,000 person-years (eg, residents in southern China and Hong Kong), these two approaches yielded similar numbers needed to screen (EBV antibody score: 5,656-1,131; EBV DNA algorithm: 5,365-1,073); positive predictive values ranged from 0.4% to 1.7% and 1.0% to 4.7%, respectively. CONCLUSION We demonstrated high sensitivity and specificity of EBV antibody and plasma EBV DNA for NPC detection, with slightly inferior performance of the EBV antibody score. Cost-effectiveness studies are needed to guide screening implementation.

oncology
Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma

W. K. Jacky Lam,Peiyong Jiang,K. C. Allen Chan,Suk H. Cheng,Haiqiang Zhang,Wenlei Peng,O. Y. Olivia Tse,Yu K. Tong,Wanxia Gai,Benny C. Y. Zee,Brigette B. Y.,Edwin P. Hui,Anthony T. C. Chan,John K. S. Woo,Rossa W. K. Chiu,Y. M. Dennis Lo,Brigette B. Y. Ma

DOI: https://doi.org/10.1073/pnas.1804184115

IF: 11.1

2018-05-14

Proceedings of the National Academy of Sciences

Abstract:Significance We identified differentiating molecular characteristics of plasma EBV DNA between nasopharyngeal carcinoma (NPC) patients and non-NPC subjects. Sequencing-based analysis revealed higher amounts of plasma EBV DNA and generally longer fragment lengths of plasma viral molecules in NPC patients than in non-NPC subjects. Based on these findings, we have developed a highly accurate blood-based test for screening of NPC. Such an approach is shown to enhance the positive predictive value and demonstrate a superior performance for NPC screening. It also obviates the need of a follow-up blood sample and therefore allows single time-point testing. We believe that this more clinically practical protocol would facilitate NPC screening on a population scale.
Expression of Epstein-Barr Virus DNA in Peripheral Blood Lymphocytes and Plasma in Patients with EBV-Associated Diseases

Jing YU,Lin WANG,Li-hua LU,Xia-feng WU,Xiao-yi LIU,Yin-han ZHANG

DOI: https://doi.org/10.3969/j.issn.1671-7414.2017.06.004

2017-01-01

Abstract:Objective To explore the expression of Epstein-Barr virus DNA(EBV DNA)in the peripheral blood lymphocytes and plasma of patients with EBV-associated diseases.Methods The whole blood samples were collected from 112 patients with suspected EB virus infection diseases,including 14 cases of nasopharyngeal carcinoma(NPC),16 cases of infectious mononucleosis(IM),22 cases of lymphoma,23 cases of autoimmune disease,26 cases of upper respiratory tract infection, and 11 cases of abnormal liver function.The levels of EBV DNA in lymphocytes and plasma of the same sample were detec-ted by fluorescence quantitative PCR(FQ-PCR).Results The EBV DNA positive rates in lymphocytes and plasma of all 112 patients were 83.0%(93/112)and 27.7%(31/112)respectively,with statistically significant difference(χ2=60.02,P<0.01).The positive rate and the load of EB virus DNA in lymphocytes and plasma of 14 patients with nasopharyngeal car-cinoma(NPC)had no statistical difference(χ2=2.25,t=-1.04,all P>0.05).However,patients with lymphoma,infec-tious mononucleosis,upper respiratory tract infection,autoimmune disease or abnormal liver function,the positive rates and the concentration of EBV DNA in the plasma were dramatically lower than those in the peripheral blood lymphocytes,and the difference was statistically significant(χ2=4.17~15.06,all P<0.05;t=3.94~10.45,all P<0.01).Conclusion The detection of EB DNA in peripheral blood lymphocytes of non NPC patients by FQ-PCR might be better than that in plasma. There was no statistical difference between the detection of EBV DNA in lymphocytes and plasma of patients with nasopha-ryngeal carcinoma.Appropriate specimen type could be selected according to clinical consideration.
Identity of 'acid' beta-glucosidase and glucocerebrosidase in human spleen.

M. Ho

IF: 3.766

Biochemical Journal

Abstract:1. Glucocerebrosidase, in association with a membrane-bound ;acid' beta-glucosidase, was separated from a soluble ;neutral' beta-glucosidase that had no activity towards glucocerebroside as substrate. 2. Glucocerebrosidase, as well as ;acid' beta-glucosidase activity depended upon the association of factor P (a heat-stable, soluble, acidic glycoprotein) with factor C (a heat-labile membrane-bound protein). 3. Factor C was solubilized under certain conditions. 4. Solubilized factor C, as well as membrane-bound factor C, could be alternatively stimulated by sodium taurocholate to give both glucocerebrosidase and ;acid' beta-glucosidase activities. 5. Membrane-bound factor C reacted optimally with factor P whereas solubilized factor C was preferentially stimulated by taurocholate. 6. Factor P-dependent glucocerebrosidase activity differed in kinetic properties from the taurocholate-stimulated enzyme activity. 7. The results are discussed in the light of (a) identity of glucocerebrosidase and ;acid' beta-glucosidase, (b) application in clinical diagnosis, (c) physiological significance of the enzyme system, and (d) polygenic inheritance in adult Gaucher's disease.
Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs

Geng Hang Chen,Zhiwei Liu,Kelly J Yu,Anna E Coghill,Xiao Xia Chen,Shang Hang Xie,Dong Feng Lin,Qi Hong Huang,Yu Qiang Lu,Wei Ling,Chu Yang Lin,Zi Jian Lu,Yu Ying Fan,Lin Quan Tang,Joshua N Sampson,Hui Li,Ann D King,Jaap M Middeldorp,Allan Hildesheim,Su Mei Cao,Geng-Hang Chen,Xiao-Xia Chen,Shang-Hang Xie,Dong-Feng Lin,Qi-Hong Huang,Yu-Qiang Lu,Chu-Yang Lin,Zi-Jian Lu,Yu-Ying Fan,Lin-Quan Tang,Su-Mei Cao

DOI: https://doi.org/10.1093/clinchem/hvac032

IF: 12.114

2022-03-24

Clinical Chemistry

Abstract:Abstract Background Epstein–Barr virus (EBV) DNA detection in the nasopharynx is considered a biomarker for nasopharyngeal carcinoma (NPC). We evaluated its performance as a reflex test to triage EBV seropositives within an NPC screening program in China. Methods The study population was embedded within an ongoing NPC screening trial and included 1111 participants who screened positive for anti-EBV VCA (antibodies against EBV capsid antigens)/EBNA1 (EBV nuclear antigen1)-IgA antibodies (of 18 237 screened). Nasopharynx swabs were collected/tested for EBNA1 gene EBV DNA load. We evaluated performance of EBV DNA in the nasopharynx swab as a reflex test to triage EBV serological high-risk (those referred to endoscopy/MRI) and medium-risk (those referred to accelerated screening) individuals. Results By the end of 2019, we detected 20 NPC cases from 317 serological high-risk individuals and 4 NPC cases from 794 medium-risk individuals. When used to triage serological high-risk individuals, nasopharynx swab EBV DNA was detected in 19/20 cases (positivity rate among cases: 95.0%; 95% CI, 75.1%–99.9%), with a referral rate of 63.4% (201/317, 95% CI, 57.8%–68.7%) and NPC detection rate among positives of 9.5% (19/201, 95% CI, 5.8%–14.4%). The performance of an algorithm that combined serology with triage of serology high-risk individuals using EBV DNA testing yielded a sensitivity of 72.4% (95% CI, 3.0%-81.4%) and specificity of 97.6% (95% CI, 97.2%-97.9%). When used to triage EBV serological medium-risk individuals, the positivity rate among cases was 75.0% (95% CI, 19.4%-99.4%), with a referral rate of 61.8% (95% CI, 58.4%-65.2%) and NPC detection rate among positives of 0.6% (95% CI, 0.1%-1.8%). Conclusions Nasopharynx swab EBV DNA showed promise as a reflex test to triage serology high-risk individuals, reducing referral by ca. 40% with little reduction in sensitivity compared to a serology-only screening program.

medical laboratory technology
Performance evaluation of magnetic bead nucleic acid extraction in real-time fluorescence quantitative PCR detection system for plasma EBV-DNA

Yuhong ZHENG,Fengjin ZHONG,Yansong CHEN,Yingying LIN,Zhenzhou XIAO,Jianji PAN,Shaojun LIN,Qiaojuan GUO,Yan CHEN

2017-01-01

Abstract:Objective To evaluate the application performance of magnetic bead nucleic acid extraction method in realtime fluorescence quantitative PCR detection for plasma Epstein-Barr virus (EBV) DNA.Methods Automated magnetic bead method was used to extract nucleic acid,and combined real-time fluorescence quantitative PCR assays for quantitative EBV-DNA.The detection performance of the method was evaluated byusing the third-party reference materials.In addition,100 patients with NPC were selected,and the plasma EBV-DNA was quantitatively detected by magnetic beads method and boiling method.The correlation between the two methods was analyzed.Results In the automated magnetic bead method-based real-time fluorescence quantitative PCR detection system for EBV-DNA,the repeatability precision of the low,medium and high were all ＜3/5 TEa (TEa =target ± 0.4 lg),and the intermediate precision were all ＜ 4/5 Tea.In the range of 5.4×101-5.4×105 U/mL,there had good linear relationship.The minimum detection limit was about 3.334×101 U/mL.And the concentration of Hb interference in plasma was lower than 8.667 g/L,the results of magnetic bead test were not significantly affected.The detection results between magnetic bead method and boiling method were linearly related,and the qualitative coincidence rate was 83％.Conclusion The detection of plasma EBV-DNA by automated magnetic bead nucleic acid extraction method can achieve good detection performance.
The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases

Miao Zheng,Yuhan Bao,Jiachen Wang,Yaxian Ma,Yang Yang,Peiling Zhang,Liting Chen,Kai Zheng,Jianfeng Zhou

DOI: https://doi.org/10.1002/hon.2998

IF: 4.85

2022-04-22

Hematological Oncology

Abstract:Epstein‐Barr virus (EBV), characterized as an omnipresent virus, has been found able to infect NK cells and leads to NK‐cell type EBV‐positive lymphoproliferative diseases (EBV‐NK‐LPDs). We retrospective analysed 202 EBV‐NK‐LPDs (including 64 CAEBV‐NK, 27 ANKL, and 111 ENKTL) patients' relationships between EBV DNA copies laboratory test results and clinical features. In CAEBV‐NK cohort, EBV DNA loads in either plasma or PBMCs had significant differences between the active state and the inactive state. Receiver operating characteristic (ROC) curves were used to measure the diagnosis accuracy of EBV DNA copies. After comparing the area under the curve (AUC), EBV DNA loads in plasma had significantly higher accuracy in distinguishing disease activation than in PBMCs. Therefore, we propose redefining CAEBV‐NK diagnosis criteria as increased EBV DNA copies in plasma (over 7.1×102 copies/ml) instead of in peripheral blood. In ANKL and ENKTL cohorts, patients who received effective therapy had significantly lower EBV DNA copies in plasma & PBMCs than in those with ineffective therapy. The significant and consistent decline indicated EBV DNA loads in plasma being a more sensitive biomarker in monitoring EBV‐NK‐LPDs therapy responses. Hemophagocytic lymphohistiocytosis (HLH) can occur secondary to EBV‐NK‐LPDs, mostly associated with a poor prognosis, so we try to estimate the combination of HLH by monitoring EBV DNA copies. When comparing the ROC curves of EBV DNA copies, EBV DNA loads in plasma had higher diagnosis accuracy. When the copies level over 4.16×103 copies/ml, it might indicate combining with HLH.This article is protected by copyright. All rights reserved.

oncology,hematology
Performance evaluation of the high-throughput quantitative Alinity m Epstein-Barr virus assay

D. Yitzchak Goldstein,Mark M. Sasaki,Momka Narlieva,Nhi Nhan,Tianxi Liu,April Kegl,Tanjina Akter,Tanisha Dickerson,Eriel Thornton,Patricia Jim,Stephen Young,Danijela Lucic,Julie W. Hirschhorn

DOI: https://doi.org/10.1128/spectrum.01507-24

IF: 3.7

2024-11-21

Microbiology Spectrum

Abstract:ABSTRACT Molecular testing for Epstein-Barr virus (EBV) infection is a cornerstone of care to prevent adverse outcomes in immunocompromised patients, including transplant recipients. We evaluated the analytical and clinical performance of the quantitative Alinity m EBV assay for plasma sample testing on the fully automated Alinity m platform. Assay lower limit of detection and precision were determined using commercially available panels in plasma. Alinity m EBV detected 100% of panels at 1.3 Log IU/mL, and precision ranged from 1.9% to 5.2% coefficients of variance (SD ≤ 0.14 Log IU/mL). Remnant-de-identified specimens initially tested with the Eurofins Viracor EBV Laboratory Developed Test (LDT) ( n = 357), ELITech EBV LDT ( n = 113), University of Washington (UW) LDT ( n = 151), or Roche cobas EBV assay ( n = 148) were subsequently tested with the Alinity m EBV assay. Comparison of the Alinity m EBV assay and Eurofins Viracor EBV assay demonstrated a correlation coefficient of 0.762 and mean bias of −0.48 Log IU/mL, comparison of the Alinity m EBV assay with UW LDT demonstrated a correlation coefficient of 0.970 and mean bias of −0.24 Log IU/mL, and comparison of the Alinity m EBV assay with cobas EBV demonstrated a correlation coefficient of 0.964 and mean bias of 0.35 Log IU/mL. The Alinity m EBV assay demonstrated high precision across the analytical measurement range and produced comparable results to the EBV test of record assays. These findings support the utility of the fully automated Alinity m EBV assay in transplant patient management. IMPORTANCE Epstein-Barr virus (EBV) infection and reactivation are associated with increased risk for post-transplant lymphoproliferative disorders (PTLD) in transplant recipients with the development of PTLD occurring predominantly within a year of transplant. Quantitative PCR for EBV is used to monitor the viral load of EBV with a negative result as a good negative predictor of PTLD. Nucleic acid amplification tests (NAATs) with high sensitivity and specificity are available on fully automated high-throughput instruments to provide accurate quantitation and improve test result turn-around time. This study evaluates the analytical and clinical performance of one such NAAT, the Alinity m EBV assay.

microbiology
Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker

Mai Abdel Haleem Abusalah,Siti Asma Binti Hassan,Norhafiza Mat Lazim,Baharudin Abdullah,Wan Fatihah Binti Wan Sohaimi,Azlan Husin,Kueh Yee Cheng,Chan Yean Yean

DOI: https://doi.org/10.3390/diagnostics11101761

2021-09-25

Abstract:Nasopharyngeal carcinoma (NPC) is an epithelial tumor with high prevalence in southern China and Southeast Asia. NPC is well associated with the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) 30 bp deletion by having its vital role in increased tumorigenicity and decreased immune recognition of EBV-related tumors. This study developed an InnoPrimers-duplex qPCR for detection of NPC blood circulating LMP1 30 bp deletion genetic biomarker for early diagnosis and treatment response prediction of NPC patients. The analytical and diagnostic evaluation and treatment response prediction were conducted using NPC patients' whole blood (WB) and tissue samples and non-NPC cancer patients and healthy individuals' WB samples. The assay was able to detect as low as 20 ag DNA per reaction (equivalent to 173 copies) with high specificity against broad reference microorganisms and archive NPC biopsy tissue and FNA samples. The diagnostic sensitivity and specificity were 83.3% and 100%, respectively. The 30 bp deletion genetic biomarker was found to be a good prognostic biomarker associated with overall clinical outcome of NPC WHO type III patients. This sensitive and specific assay can help clinicians in early diagnosis and treatment response prediction of NPC patients, which will enhance treatment outcome and lead to better life-saving.
Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma

Guo-Ying Liu,Wei-Xiong Xia,Zhuo-Fei Bi,Nian Lu,Wang-Zhong Li,Wei-Xin Bei,Hu Liang,Jun-Zhi Xie,Yi-Min Liu,He-Rui Yao,Yan-Qun Xiang

DOI: https://doi.org/10.3389/fonc.2022.860700

IF: 4.7

2022-06-10

Frontiers in Oncology

Abstract:Background: Plasma Epstein–Barr virus DNA (EBV-DNA) is a sensitive and specific biomarker for nasopharyngeal carcinoma (NPC). We investigated whether longitudinal monitoring of EBV-DNA could accurately detect clinical disease progression in NPC patients with bone-only metastases. Methods: In this retrospective study, a total of 105 patients with bone-only metastatic NPC who were treated with platinum-based first-line chemotherapy were enrolled. Undetectable EBV-DNA after first-line chemotherapy was defined as a biochemical complete response (BCR). The correlation of the EBV-DNA dynamic status with overall survival (OS) and progression-free survival (PFS) was determined by Cox regression. The correlation between non-normalized EBV-DNA period and PFS period was determined. Results: After a median follow-up time of 53.4 months [Interquartile range (IQR): 42.8–80.6], 64 patients had disease progression. Thirty-nine of 105 patients (37.1%) had a BCR at all follow-up time points, and none of these 39 patients had disease progression, corresponding to a negative predictive value (NPV) of 100%. Sixty-six patients had a detectable EBV-DNA during surveillance, with 64 diagnosed as disease progression at the last follow-up, for a positive predictive value (PPV) of 97.0%. Actuarial 3-year OS rates were 45.0% for patients with detectable EBV-DNA during posttreatment surveillance and 100% for patients with undetectable EBV-DNA. Lastly, median lead time between non-normalized EBV-DNA and clinically proven progression was 5.87 ± 0.67 months. Conclusions: Taken together, EBV-DNA provided predictive value for the bone-only metastatic NPC patients. The results should be validated in prospective randomized studies.

oncology
Bacterial leakage along the implant-abutment interface of premachined or cast components.

C. Nascimento,Rodrigo Edson Santos Barbosa,J. P. M. Issa,Evandro Watanabe,Izabel Yoko Ito,Rubens Ferreira Jr. Albuquerque

DOI: https://doi.org/10.1016/J.IJOM.2007.07.026

2008-02-01

Abstract:
Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells.

Shanwen Chen,Jing Zhu,Ju Ma,Jun-ling Zhang,S. Zuo,Guowei Chen,Xin Wang,Yisheng Pan,Yucun Liu,Peng-yuan Wang

DOI: https://doi.org/10.3892/ol.2017.6390

2017-08-01

Oncology Letters

Abstract:Long non-coding RNA-imprinted maternally expressed transcript (non-protein coding) (H19) has been previously identified to be involved in the development of a number of types of cancer. However, the function of H19 in the pathogenesis of colorectal cancer remains unclear. The expression level of H19 in colorectal tumor tissues, and the association between H19 expression and clinicopathological variables and prognosis was investigated in the present study. In addition, the effect of H19 overexpression on viability, migration and epithelial-mesenchymal transition (EMT) of colon cancer cells was investigated in HCT-116 and SW-480 cells. The results of the present study suggest that overexpression of H19 is associated with decreased recurrence-free survival and overall survival rates in patients with colorectal cancer, and increased viability and migration in colon cancer cells. The induction of the EMT process may be an underlying molecular mechanism associated with the H19-induced increased metastasis potential of colon cancer cells.
Multiple cross displacement amplification combined with nanoparticle-based lateral flow biosensor for rapid and sensitive detection of Epstein-Barr virus

Xinbei Jia,Juan Zhou,Fei Xiao,Xiaolan Huang,Wenqiang He,Wen Hu,Yaru Kong,Weiheng Yan,Jie Ji,Yuwei Qi,Yi Wang,Jun Tai

DOI: https://doi.org/10.3389/fcimb.2023.1321394

IF: 6.073

2024-01-08

Frontiers in Cellular and Infection Microbiology

Abstract:Introduction: Epstein-Barr virus (EBV) is a highly dangerous virus that is globally prevalent and closely linked to the development of nasopharyngeal cancer (NPC). Plasma EBV DNA analysis is an effective strategy for early detection, prognostication and monitoring of treatment response of NPC. Methods: Here, we present a novel molecular diagnostic technique termed EBV-MCDA-LFB, which integrates multiple cross displacement amplification (MCDA) with nanoparticle-based lateral flow (LFB) to enable simple, rapid and specific detection of EBV. In the EBV-MCDA-LFB system, a set of 10 primers was designed for rapidly amplifying the highly conserved tandem repeat BamHI-W region of the EBV genome. Subsequently, the LFB facilitate direct assay reading, eliminating the use of extra instruments and reagents. Results: The outcomes showed that the 65°C within 40 minutes was the optimal reaction setting for the EBV-MCDA system. The sensitivity of EBV-MCDA-LFB assay reached 7 copies per reaction when using EBV recombinant plasmid, and it showed 100% specificity without any cross-reactivity with other pathogens. The feasibility of the EBV-MCDA-LFB method for EBV detection was successfully validated by 49 clinical plasma samples. The complete detection process, consisting of rapid template extraction (15 minutes), MCDA reaction (65°C for 40 minutes), and LFB result reading (2 minutes), can be finalized within a 60-minutes duration. Discussion: EBV-MCDA-LFB assay designed here is a fast, extremely sensitive and specific technique for detecting EBV in field and at the point-of-care (PoC), which is especially beneficial for countries and regions with a high prevalence of the disease and limited economic resources.

immunology,microbiology
Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Lu Ping Tan,Geok Wee Tan,Vijaya Mohan Sivanesan,Siang Ling Goh,Xun Jin Ng,Chun Shen Lim,Wee Ric Kim,Taznim Begam Binti Mohd Mohidin,Nor Soleha Mohd Dali,Siew Hoon Ong,Chun Ying Wong,Halimuddin Sawali,Yoke Yeow Yap,Faridah Hassan,Kin Choo Pua,Cheng Eng Koay,Ching Ching Ng,Alan Soo-Beng Khoo,Malaysian Nasopharyngeal Carcinoma Study Group

DOI: https://doi.org/10.1002/ijc.32656

2020-04-15

Abstract:Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein-Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.
Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal Cancer

K C Allen Chan,W K Jacky Lam,Ann King,Vivien S Lin,Patrick P H Lee,Benny C Y Zee,Stephen L Chan,Irene O L Tse,Amy F C Tsang,Maggie Z J Li,Peiyong Jiang,Qi Yong H Ai,Darren M C Poon,K H Au,Edwin P Hui,Brigette B Y Ma,Andrew C Van Hasselt,Anthony T C Chan,John K S Woo,Y M Dennis Lo

DOI: https://doi.org/10.1056/EVIDoa2200309

Abstract:BACKGROUND: We previously conducted a prospective study to show that nasopharyngeal cancer (NPC) screening with circulating Epstein–Barr virus (EBV) DNA analysis can improve survival. However, the long-term significance of positive results in individuals without cancer was unclear. METHODS: We conducted a second-round screening at a median of 43 months after the initial screening. Participants with detectable plasma EBV DNA were retested in 4 weeks, and those with persistently positive results were investigated with nasal endoscopy and magnetic resonance imaging. RESULTS: Of the 20,174 volunteers who participated in the first-round screening, 17,838 (88.6%) were rescreened. Among them, 423 (2.37%) had persistently detectable plasma EBV DNA. Twenty-four patients were identified as having NPC. A significantly higher proportion of patients had stage I/II cancer than in a historical cohort (67% vs. 20%; chi-square test, P<0.001), and they had superior 3-year progression-free survival (100% vs. 78.8%). Compared with participants with undetectable plasma EBV DNA in the first round of screening, participants with transiently and persistently positive results in the first round were more likely to have a cancer identified in the second round, with relative risks of 4.4 (95% confidence interval, 1.3 to 15.0) and 16.8 (95% confidence interval, 5.7 to 49.6), respectively. CONCLUSIONS: Individuals with detectable plasma EBV DNA but without an immediately identifiable NPC were more likely to have the cancer identified in another round of screening performed 3 to 5 years later. (Funded by Kadoorie Charitable Foundation and others; ClinicalTrials.gov number, NCT02063399.)

Transesophageal color Doppler diagnosis of anomalous origin of left circumflex coronary artery.

Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer

Quantification of low-level Cytomegalovirus and Epstein-Barr virus DNAemia by digital PCR

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas

Evaluation of Performance and Application of Three Nucleic Acid Extraction Methods for Quantification of Plasma Epstein-Barr Virus DNA

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

Performance and Operational Feasibility of Epstein-Barr Virus–Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches

Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma

Expression of Epstein-Barr Virus DNA in Peripheral Blood Lymphocytes and Plasma in Patients with EBV-Associated Diseases

Identity of 'acid' beta-glucosidase and glucocerebrosidase in human spleen.

Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs

Performance evaluation of magnetic bead nucleic acid extraction in real-time fluorescence quantitative PCR detection system for plasma EBV-DNA

The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases

Performance evaluation of the high-throughput quantitative Alinity m Epstein-Barr virus assay

Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma

Bacterial leakage along the implant-abutment interface of premachined or cast components.

Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells.

Multiple cross displacement amplification combined with nanoparticle-based lateral flow biosensor for rapid and sensitive detection of Epstein-Barr virus

Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal Cancer